|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan YL, Zheng M, Tang YL and Liang XH: A
new perspective of vasculogenic mimicry: EMT and cancer stem cells
(Review). Oncol Lett. 6:1174–1180. 2013.PubMed/NCBI
|
|
3
|
Gidekel S, Pizov G, Bergman Y and Pikarsky
E: Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer
Cell. 4:361–370. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nichols J, Zevnik B, Anastassiadis K, Niwa
H, Klewe-Nebenius D, Chambers I, Schöler H and Smith A: Formation
of pluripotent stem cells in the mammalian embryo depends on the
POU transcription factor Oct4. Cell. 95:379–391. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chambers I, Colby D, Robertson M, Nichols
J, Lee S, Tweedie S and Smith A: Functional expression cloning of
Nanog, a pluripotency sustaining factor in embryonic stem cells.
Cell. 113:643–655. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Costi MP and Ferrari S: Update on
antifolate drugs targets. Curr Drug Targets. 2:135–166. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hattinger CM, Reverter-Branchat G,
Remondini D, Castellani GC, Benini S, Pasello M, Manara MC,
Scotlandi K, Picci P and Serra M: Genomic imbalances associated
with methotrexate resistance in human osteosarcoma cell lines
detected by comparative genomic hybridization-based techniques. Eur
J Cell Biol. 82:483–493. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Serra M, Reverter-Branchat G, Maurici D,
Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M,
Scotlandi K and Picci P: Analysis of dihydrofolate reductase and
reduced folate carrier gene status in relation to methotrexate
resistance in osteosarcoma cells. Ann Oncol. 15:151–160. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ,
Tsai TH, Chou SH, Chien CS, Ku HH and Lo JF: Positive correlations
of Oct-4 and Nanog in oral cancer stem-like cells and high-grade
oral squamous cell carcinoma. Clin Cancer Res. 14:4085–4095. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang JC: Evaluating therapeutic efficacy
against cancer stem cells: New challenges posed by a new paradigm.
Cell Stem Cell. 1:497–501. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dean M: ABC transporters, drug resistance,
and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Basu-Roy U, Seo E, Ramanathapuram L, Rapp
TB, Perry JA, Orkin SH, Mansukhani A and Basilico C: Sox2 maintains
self renewal of tumor-initiating cells in osteosarcomas. Oncogene.
31:2270–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Fiore R, Santulli A, Ferrante RD,
Giuliano M, De Blasio A, Messina C, Pirozzi G, Tirino V, Tesoriere
G and Vento R: Identification and expansion of human
osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide
treatment. J Cell Physiol. 219:301–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adhikari AS, Agarwal N, Wood BM, Porretta
C, Ruiz B, Pochampally RR and Iwakuma T: CD117 and Stro-1 identify
osteosarcoma tumor-initiating cells associated with metastasis and
drug resistance. Cancer Res. 70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tirino V, Desiderio V, d'Aquino R, De
Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De
Rosa A, Papaccio G and Giordano A: Detection and characterization
of CD133+ cancer stem cells in human solid tumours. PLoS One.
3:e34692008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tirino V, Desiderio V, Paino F, De Rosa A,
Papaccio F, Fazioli F, Pirozzi G and Papaccio G: Human primary bone
sarcomas contain CD133+ cancer stem cells displaying high
tumorigenicity in vivo. FASEB J. 25:2022–2030. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saini V, Hose CD, Monks A, Nagashima K,
Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, et
al: Identification of CBX3 and ABCA5 as putative biomarkers for
tumor stem cells in osteosarcoma. PLoS One. 7:e414012012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pascal LE, Oudes AJ, Petersen TW, Goo YA,
Walashek LS, True LD and Liu AY: Molecular and cellular
characterization of ABCG2 in the prostate. BMC Urol. 7:62007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bunting KD: ABC transporters as phenotypic
markers and functional regulators of stem cells. Stem Cells.
20:11–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park IH, Zhao R, West JA, Yabuuchi A, Huo
H, Ince TA, Lerou PH, Lensch MW and Daley GQ: Reprogramming of
human somatic cells to pluripotency with defined factors. Nature.
451:141–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okita K, Ichisaka T and Yamanaka S:
Generation of germline-competent induced pluripotent stem cells.
Nature. 448:313–317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seigel GM, Hackam AS, Ganguly A, Mandell
LM and Gonzalez-Fernandez F: Human embryonic and neuronal stem cell
markers in retinoblastoma. Mol Vis. 13:823–832. 2007.PubMed/NCBI
|
|
26
|
Santagata S, Ligon KL and Hornick JL:
Embryonic stem cell transcription factor signatures in the
diagnosis of primary and metastatic germ cell tumors. Am J Surg
Pathol. 31:836–845. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO,
Zheng BJ and Guan XY: Identification and characterization of
tumorigenic liver cancer stem/progenitor cells. Gastroenterology.
132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Freberg CT, Dahl JA, Timoskainen S and
Collas P: Epigenetic reprogramming of OCT4 and NANOG regulatory
regions by embryonal carcinoma cell extract. Mol Biol Cell.
18:1543–1553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hoei-Hansen CE, Kraggerud SM, Abeler VM,
Kaern J, Rajpert-De Meyts E and Lothe RA: Ovarian dysgerminomas are
characterised by frequent KIT mutations and abundant expression of
pluripotency markers. Mol Cancer. 6:122007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Trosko JE: From adult stem cells to cancer
stem cells: Oct-4 Gene, cell-cell communication, and hormones
during tumor promotion. Ann N Y Acad Sci. 1089:36–58. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pan G and Thomson JA: Nanog and
transcriptional networks in embryonic stem cell pluripotency. Cell
Res. 17:42–49. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang J, Espinoza LA, Kinders RJ, Lawrence
SM, Pfister TD, Zhou M, Veenstra TD, Thorgeirsson SS and Jessup JM:
NANOG modulates stemness in human colorectal cancer. Oncogene.
32:4397–4405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jeter CR, Liu B, Liu X, Chen X, Liu C,
Calhoun-Davis T, Repass J, Zaehres H, Shen JJ and Tang DG: NANOG
promotes cancer stem cell characteristics and prostate cancer
resistance to androgen deprivation. Oncogene. 30:3833–3845. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ibrahim EE, Babaei-Jadidi R, Saadeddin A,
Spencer-Dene B, Hossaini S, Abuzinadah M, Li N, Fadhil W, Ilyas M,
Bonnet D and Nateri AS: Embryonic NANOG activity defines colorectal
cancer stem cells and modulates through AP1- and TCF-dependent
mechanisms. Stem Cells. 30:2076–2087. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang L, Zhang X, Zhang M, Zhang J, Sheng
Y, Sun X, Chen Q and Wang LX: Increased Nanog expression promotes
tumor development and Cisplatin resistance in human esophageal
cancer cells. Cell Physiol Biochem. 30:943–952. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Serra M, Scotlandi K, Manara MC, Maurici
D, Lollini PL, De Giovanni C, Toffoli G and Baldini N:
Establishment and characterization of multidrug-resistant human
osteosarcoma cell lines. Anticancer Res. 13:323–329.
1993.PubMed/NCBI
|
|
38
|
Scotlandi K, Serra M, Manara MC, Lollini
PL, Maurici D, Del Bufalo D and Baldini N: Pre-treatment of human
osteosarcoma cells with N-methylformamide enhances P-glycoprotein
expression and resistance to doxorubicin. Int J Cancer. 58:95–101.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Taylor CW, Dalton WS, Parrish PR, Gleason
MC, Bellamy WT, Thompson FH, Roe DJ and Trent JM: Different
mechanisms of decreased drug accumulation in doxorubicin and
mitoxantrone resistant variants of the MCF7 human breast cancer
cell line. Br J Cancer. 63:923–929. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rajkumar T and Yamuna M: Multiple pathways
are involved in drug resistance to doxorubicin in an osteosarcoma
cell line. Anticancer Drugs. 19:257–265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen CJ, Chin JE, Ueda K, Clark DP, Pastan
I, Gottesman MM and Roninson IB: Internal duplication and homology
with bacterial transport proteins in the mdr1 (P-glycoprotein) gene
from multidrug-resistant human cells. Cell. 47:381–389. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Baldini N, Scotlandi K, Barbanti-Bròdano
G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S,
Campanacci M, et al: Expression of P-glycoprotein in high-grade
osteosarcomas in relation to clinical outcome. N Engl J Med.
333:1380–1385. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Baldini N, Scotlandi K, Serra M, Picci P,
Bacci G, Sottili S and Campanacci M: P-glycoprotein expression in
osteosarcoma: A basis for risk-adapted adjuvant chemotherapy. J
Orthop Res. 17:629–632. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ferrari S and Palmerini E: Adjuvant and
neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr
Opin Oncol. 19:341–346. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
